Skip to main content
SpringerLink
Log in

Epstein-Barr Virus Lymphomagenesis and Therapeutic Targets

  • Chapter
  • First Online:
Non-Hodgkin Lymphoma

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1078 Accesses

Abstract

The pathogenic role of the Epstein-Barr virus (EBV) has been suggested because it is consistently found in some lymphoproliferative disorders. More than 90% of the population is exposed to the virus, usually during childhood, and after initial exposure, the virus survives for the lifetime of individuals as an episome, and expresses a limited set of proteins depending on the immune status of the host. The variable expression of viral proteins is known as latency pattern with minimal expression of viral products in immunocompetent hosts, but expression of numerous viral products in the immunocompromised host. Thus, the more virus products that are expressed, the more targets for an immune reaction. Since it is acknowledged that the neoplastic process including lymphoproliferative disorders result from a multistep chain of events, multiple pathways are affected, and in particular in EBV-positive lymphoproliferations, EBV products interact with abnormally activated pathways in the context of the immune response of the host. In this review we analyze the structure of the virus and its interaction in the immunocompetent as well as in the immunocompromised host, and discuss the possible roles of EBV products in various lymphoproliferative disorders. Finally, we discuss the potential role of expressed EBV viral proteins and activation of pathogenic pathways in the setting of specific diagnostic categories with the identification of potential molecular targets.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roschewski M, Wilson WH (2012) EBV-associated lymphomas in adults. Best Pract Res Clin Haematol 25:75–89

    Article  PubMed  Google Scholar 

  2. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR (1987) Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/c3d receptor of B cells: sequence homology of gp350 and c3 complement fragment c3d. J Virol 61:1416–1420

    PubMed  CAS  Google Scholar 

  3. Kieff E, Rickinson A (2001) Epstein-Barr virus. In: Knipe D, Howley P (eds) Fields virology, 4th edn. Lippincott, Philadelpia, PA, pp 2511–2573

    Google Scholar 

  4. Kieff E, Richardson AB (2007) Epstein-Barr virus and its replication. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 2603–2654

    Google Scholar 

  5. Castillo JJ, Beltran BE, Miranda RN, Paydas S, Winer ES, Butera JN (2011) Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 16:87–96

    Article  PubMed  Google Scholar 

  6. Qiu J, Cosmopoulos K, Pegtel M et al (2011) A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 7:e1002193

    Article  PubMed  CAS  Google Scholar 

  7. Bornkamm GW (2009) Epstein-Barr virus and its role in the pathogenesis of Burkitt’s lymphoma: an unresolved issue. Semin Cancer Biol 19:351–365

    Article  PubMed  CAS  Google Scholar 

  8. Cader FZ, Kearns P, Young L, Murray P, Vockerodt M (2010) The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev 36:348–353

    Article  PubMed  Google Scholar 

  9. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1:702–703

    Article  PubMed  CAS  Google Scholar 

  10. Kuppers R (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5:251–262

    Article  PubMed  Google Scholar 

  11. Scheller H, Tobollik S, Kutzera A et al (2010) c-Myc overexpression promotes a germinal center-like program in Burkitt’s lymphoma. Oncogene 29:888–897

    Article  PubMed  CAS  Google Scholar 

  12. Allday MJ (2009) How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma? Semin Cancer Biol 19:366–376

    Article  PubMed  CAS  Google Scholar 

  13. Bieging KT, Swanson-Mungerson M, Amick AC, Longnecker R (2010) Epstein-Barr virus in Burkitt’s lymphoma: a role for latent membrane protein 2A. Cell Cycle 9:901–908

    Article  PubMed  CAS  Google Scholar 

  14. Guikema JE, de Boer C, Haralambieva E et al (2006) IGH switch breakpoints in Burkitt lymphoma: exclusive involvement of noncanonical class switch recombination. Genes Chromosomes Cancer 45:808–819

    Article  PubMed  CAS  Google Scholar 

  15. Bellan C, Lazzi S, Hummel M et al (2005) Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 106:1031–1036

    Article  PubMed  CAS  Google Scholar 

  16. Preudhomme C, Dervite I, Wattel E et al (1995) Clinical significance of p53 mutations in newly diagnosed Burkitt’s lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 13:812–820

    PubMed  CAS  Google Scholar 

  17. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991) p53 is frequently mutated in Burkitt’s lymphoma cell lines. EMBO J 10:2879–2887

    PubMed  CAS  Google Scholar 

  18. Kang MS, Hung SC, Kieff E (2001) Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci U S A 98:15233–15238

    Article  PubMed  CAS  Google Scholar 

  19. Gruhne B, Sompallae R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG (2009) The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A 106:2313–2318

    Article  PubMed  CAS  Google Scholar 

  20. Saridakis V, Sheng Y, Sarkari F et al (2005) Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18:25–36

    Article  PubMed  CAS  Google Scholar 

  21. Bell AI, Groves K, Kelly GL et al (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt’s lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87:2885–2890

    Article  PubMed  CAS  Google Scholar 

  22. Fruehling S, Swart R, Dolwick KM, Kremmer E, Longnecker R (1998) Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 72:7796–7806

    PubMed  CAS  Google Scholar 

  23. Swanson-Mungerson MA, Caldwell RG, Bultema R, Longnecker R (2005) Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol 79:7355–7362

    Article  PubMed  CAS  Google Scholar 

  24. Portis T, Longnecker R (2004) Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23:8619–8628

    Article  PubMed  CAS  Google Scholar 

  25. Merchant M, Longnecker R (2001) LMP2A survival and developmental signals are ­transmitted through Btk-dependent and Btk-independent pathways. Virology 291:46–54

    Article  PubMed  CAS  Google Scholar 

  26. Engels N, Merchant M, Pappu R, Chan AC, Longnecker R, Wienands J (2001) Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med 194:255–264

    Article  PubMed  CAS  Google Scholar 

  27. Wong HH, Wang J (2009) Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma 50:335–340

    Article  PubMed  CAS  Google Scholar 

  28. Asano N, Yamamoto K, Tamaru J et al (2009) Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 113:2629–2636

    Article  PubMed  CAS  Google Scholar 

  29. Oyama T, Ichimura K, Suzuki R et al (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26

    Article  PubMed  Google Scholar 

  30. Lages CS, Suffia I, Velilla PA et al (2008) Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 181:1835–1848

    PubMed  CAS  Google Scholar 

  31. Park S, Lee J, Ko YH et al (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110:972–978

    Article  PubMed  CAS  Google Scholar 

  32. Kapatai G, Murray P (2007) Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 60:1342–1349

    Article  PubMed  CAS  Google Scholar 

  33. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES (2008) Classic Hodgkin lymphoma, introduction. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, p 326

    Google Scholar 

  34. Hummel M, Anagnostopoulos I, Dallenbach F, Korbjuhn P, Dimmler C, Stein H (1992) EBV infection patterns in Hodgkin’s disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br J Haematol 82:689–694

    Article  PubMed  CAS  Google Scholar 

  35. Marafioti T, Hummel M, Foss HD et al (2000) Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95:1443–1450

    PubMed  CAS  Google Scholar 

  36. Kuppers R, Hajadi M, Plank L et al (1996) Molecular Ig gene analysis reveals that monocytoid B cells lymphoma is a malignancy of mature B cells carrying somatically mutated V region genes and suggests that rearrangement of the kappa-deleting element(resulting in deletion of the Ig kappa enhancers) abolishes somatic hypermutation in the human. Eur J Immunol 26:1794–1800

    Article  PubMed  CAS  Google Scholar 

  37. Kanzler H, Kuppers R, Hansmann ML et al (1996) Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the out growth of a dominant tumor clone derived from(crippled) germinal center B cells. J Exp Med 184:1495–1505

    Article  PubMed  CAS  Google Scholar 

  38. Kuppers R (2002) Molecular biology of Hodgkin’s lymphoma. Adv Cancer Res 84:277–312

    Article  PubMed  Google Scholar 

  39. Farrell K, Jarrett RF (2011) The molecular pathogenesis of Hodgkin lymphoma. Histopathology 58:15–25

    Article  PubMed  Google Scholar 

  40. Gulley ML, Eagan PA, Quintanilla-Martinez L et al (1994) Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin’s disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83:1595–1602

    PubMed  CAS  Google Scholar 

  41. Lam N, Sugden B (2003) CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 15:9–16

    Article  PubMed  CAS  Google Scholar 

  42. Graham JP, Arcipowski KM, Bishop GA (2010) Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 237:226–248

    Article  PubMed  CAS  Google Scholar 

  43. Rastelli J, Homig-Holzel C, Seagal J et al (2008) LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood 111:1448–1455

    Article  PubMed  CAS  Google Scholar 

  44. Pratt ZL, Zhang J, Sugden B (2012) The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells. J Virol 86:4380–4393

    Article  PubMed  CAS  Google Scholar 

  45. He Z, Xin B, Yang X, Chan C, Cao L (2000) Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res 60:1845–1848

    PubMed  CAS  Google Scholar 

  46. Cahir-McFarland ED, Carter K, Rosenwald A et al (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency ­III-infected cells. J Virol 78:4108–4119

    Article  PubMed  CAS  Google Scholar 

  47. Lee IS, Kim SH, Song HG, Park SH (2003) The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin’s lymphoma. Into J Hematology 77:330–335

    Article  CAS  Google Scholar 

  48. Cohen JI, Bollard CM, Khanna R, Pittaluga S (2008) Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma 49(Suppl 1):27–34

    Article  PubMed  CAS  Google Scholar 

  49. Aizawa S, Nakano H, Ishida T et al (1997) Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 272:2042–2045

    Article  PubMed  CAS  Google Scholar 

  50. Longnecker R (2000) Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79:175–200

    Article  PubMed  CAS  Google Scholar 

  51. Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA (2007) The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin’s lymphoma. Exp Hematology 35:596–604

    Article  CAS  Google Scholar 

  52. Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13:577–585

    Article  PubMed  Google Scholar 

  53. Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200:1623–1633

    Article  PubMed  CAS  Google Scholar 

  54. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757–768

    Article  PubMed  CAS  Google Scholar 

  55. Kimura H, Ito Y, Kawabe S et al (2012) EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119:673–686

    Article  PubMed  CAS  Google Scholar 

  56. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES (2009) Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol 20:1472–1482

    Article  PubMed  CAS  Google Scholar 

  57. Yang L, Aozasa K, Oshimi K, Takada K (2004) Epstein-Barr virus (EBV)-encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction. Cancer Res 64:5332–5337

    Article  PubMed  CAS  Google Scholar 

  58. Kim A, Lee JE, Jang WS et al (2012) A combination of methotrexate and irradiation promotes cell death in NK/T-cell lymphoma cells via down-regulation of NF-kappaB signaling. Leuk Res 36:350–357

    Article  PubMed  CAS  Google Scholar 

  59. Sharifi R, Sinclair JC, Gilmour KC et al (2004) SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103:3821–3827

    Article  PubMed  CAS  Google Scholar 

  60. Booth C, Gilmour KC, Veys P et al (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117:53–62

    Article  PubMed  CAS  Google Scholar 

  61. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587–617

    Article  PubMed  CAS  Google Scholar 

  62. Raphael M, Said J, Borisch B, Cesarman E, Harris NL (2008) Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 340–342

    Google Scholar 

  63. Bibas M, Antinori A (2009) EBV and HIV-related lymphoma. Mediterr J Hematology Infect Dis 1:e2009032

    Google Scholar 

  64. Feng WH, Cohen JI, Fischer S et al (2004) Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96:1691–1702

    Article  PubMed  CAS  Google Scholar 

  65. Balandraud N, Roudier J, Roudier C (2005) What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum 34:31–33

    Article  PubMed  CAS  Google Scholar 

  66. Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B (2004) T-cell ­post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. Br J Haematol 127:429–432

    Article  PubMed  CAS  Google Scholar 

  67. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004) Demonstration of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 101:239–244

    Article  PubMed  CAS  Google Scholar 

  68. Mautner J, Bornkamm GW (2012) The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection. Eur J Cell Biol 91:31–35

    Article  PubMed  CAS  Google Scholar 

  69. Robertson ES, Lin J, Kieff E (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70(5):3068–3074

    PubMed  CAS  Google Scholar 

  70. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B (2004) The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23:1342–1353

    Article  PubMed  CAS  Google Scholar 

  71. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene 27:421–433

    Article  PubMed  CAS  Google Scholar 

  72. Radkov SA, Touitou R, Brehm A et al (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73:5688–5697

    PubMed  CAS  Google Scholar 

  73. Parker GA, Touitou R, Allday MJ (2000) Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19:700–709

    Article  PubMed  CAS  Google Scholar 

  74. Sjoblom A, Yang WW, Palmqvist L, Jansson A, Rymo L (1998) An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol 72:1365–1376

    PubMed  CAS  Google Scholar 

  75. Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ (2008) Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 82:7456–7466

    Article  PubMed  CAS  Google Scholar 

  76. Gustafsson A, Levitsky V, Zou JZ et al (2000) Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814

    PubMed  CAS  Google Scholar 

  77. Demachi-Okamura A, Ito Y, Akatsuka Y et al (2008) Epstein-Barr virus nuclear antigen 1-specific CD4(+) T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 99:1633–1642

    Article  PubMed  CAS  Google Scholar 

  78. Kobayashi H, Nagato T, Takahara N et al (2008) Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 68:901–908

    Article  PubMed  CAS  Google Scholar 

  79. Perrine SR, Hermine O, Small T et al (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 109:2571–2578

    Article  PubMed  CAS  Google Scholar 

  80. Ansell SM, Horwitz SM, Engert A et al (2007) Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764–2769

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Cancer Center, Sun Yat-sen University, Guangzhou, 510060, China

    Huilan Rao

  2. Department of Hematopathology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA

    Roberto N. Miranda

Authors
  1. Huilan Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto N. Miranda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto N. Miranda .

Editor information

Editors and Affiliations

  1. Div. Hematology & Oncology, Rhode Island Hospital, Eddy St. 593, Providence, 02903, Rhode Island, USA

    Peter J. Quesenberry

  2. , Division of Hematology and Oncology, The Miriam Hospital, Summit Ave 164, Providence, 02906, Rhode Island, USA

    Jorge J. Castillo

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rao, H., Miranda, R.N. (2013). Epstein-Barr Virus Lymphomagenesis and Therapeutic Targets. In: Quesenberry, P., Castillo, J. (eds) Non-Hodgkin Lymphoma. Cancer Drug Discovery and Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5851-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5851-7_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5850-0

  • Online ISBN: 978-1-4614-5851-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation